Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Selumetinib with radioactive iodine therapy for differentiated thyroid cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions There are four different types of thyroid cancer, and the most common is known as differentiated thyroid cancer. It is a type of cancer which usually develops very slowly, and can often be cured by surgery. However, in a small number of patients the cancer then returns and becomes difficult to treat. Radioactive iodine therapy is often used after surgery to reduce the chance of the cancer returning.
Selumetinib is a new drug for the treatment of thyroid cancer given as a tablet twice a day. Some studies have suggested selumetinib may be helpful for patients who are at high risk of the cancer returning after surgery. More studies are now aiming to show how it may work best in combination with radioactive iodine therapy, which is currently used.
If selumetinib is licensed for use in the UK, it could be a new treatment option for patients with differentiated thyroid cancer that may reduce symptoms of the disease and increase survival. Indexing Status Subject indexing assigned by CRD MeSH Benzimidazoles; Humans; Iodine; Thyroid Neoplasms Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000528 Date abstract record published 15/03/2016 |